(±)ethyl 2-(4-nitrophenoxy)butanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (±)ethyl 2-(4-nitrophenoxy)butanoate
• 英文别名: Ethyl 2-(4-nitrophenoxy)butanoate
• 化学式: C₁₂H₁₅NO₅
• mdl: MFCD20143143
• 分子量: 253.255
• InChiKey: NZSZBYKHXVLPBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (±)ethyl 2-(4-nitrophenoxy)butanoate 在 水 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 生成 2-(4-nitro-phenoxy)-butyric acid
  参考文献：
  名称：

  Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells

  摘要：

  A family of carbonyl substituted diphenylpyrimidine derivatives (Car-DPPYs) with strong activity against focal adhesion kinase (FAK), were described in this manuscript. Among them, compounds 7a (IC50 = 5.17 nM) and 7f (IC50 = 2.58 nM) displayed equal anti-FAK enzymatic activity to the lead compound TAE226 (6.79 nM). In particular, compound 7a also exhibited strong antiproliferative activity against several stubborn cancer cells, including AsPC-1 cells (IC50 = 0.105 mu M), BxPC-3 cells (IC50 = 0.090 mu M), and MCF-7/ADR cells (IC50 = 0.59 mu M). Additionally, compound 7a also showed great antitumor efficacy in vivo via aAsPC-1 cancer Xenograft mouse model. The preliminary mechanism study by Western blot analysis revealed that 7a repressed FAK phosphorylation in AsPC cancer cells. Taken together, the results indicate that compound 7a may serve as a promising preclinical candidate for treatment of stubborn cancers. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.04.004
• 作为产物：
  描述：

  4-nitrophenol sodium salt 、 2-溴丁酸乙酯 生成 (±)ethyl 2-(4-nitrophenoxy)butanoate
  参考文献：
  名称：

  Bischoff, Chemische Berichte, 1900, vol. 33, p. 1605

  摘要：

  DOI：

文献信息

• Design and synthesis of novel quinazolinone‐based fibrates as PPARα agonists with antihyperlipidemic activity
  作者：Rasha M. Hassan、Islam H. Ali、Mohammed S. Abdel‐Maksoud、Heba M. I. Abdallah、Ahmed M. El Kerdawy、Francesca Sciandra、Iman A. Y. Ghannam

  DOI：10.1002/ardp.202100399

  日期：2022.3

  discover new antihyperlipidemic agents, a new set of quinazolinone-fibrate hybrids 9a–r bearing the essential features for peroxisome proliferator-activated receptor-α (PPARα) agonistic activity was synthesized and the structures were confirmed by different spectral data. All the target compounds were screened for their PPARα agonistic activity. Compounds 9o and 9q exhibited potent activity, with EC50

  为了发现新的抗高血脂药物，合成了一组具有过氧化物酶体增殖物激活受体-α (PPARα) 激动活性的基本特征的新型喹唑啉酮-贝特杂化物 9a-r ，并通过不同的光谱数据证实了其结构。筛选所有目标化合物的 PPARα 激动活性。化合物9o和9q表现出强效活性，EC 50值分别比非诺贝特高 8.7 倍和 27 倍。对PPARα受体活性位点中所有新合成的化合物进行分子对接研究，以研究它们在受体中的相互作用和能量。此外，使用 Triton WR-1339 诱导的高脂血症大鼠测定了化合物9o和9q的抗高脂血症和抗氧化活性。化合物9q以剂量依赖性方式表现出有效的降血脂活性，显着降低血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇和极低密度脂蛋白胆固醇水平，并增加高密度脂蛋白胆固醇水平。此外，它具有强大的抗氧化特性，显着提高了还原型谷胱甘肽的水平以及总抗氧化能力，并显着降低了丙二醛水平。组织病理学研究表明，化合
• Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells
  作者：Luhong Wang、Min Ai、Jiawen Yu、Lingling Jin、Changyuan Wang、Zhihao Liu、Xiaohong Shu、Zeyao Tang、Kexin Liu、Hui Luo、Wenshun Guan、Xiuli Sun、Xiaodong Ma

  DOI：10.1016/j.ejmech.2019.04.004

  日期：2019.6

  A family of carbonyl substituted diphenylpyrimidine derivatives (Car-DPPYs) with strong activity against focal adhesion kinase (FAK), were described in this manuscript. Among them, compounds 7a (IC50 = 5.17 nM) and 7f (IC50 = 2.58 nM) displayed equal anti-FAK enzymatic activity to the lead compound TAE226 (6.79 nM). In particular, compound 7a also exhibited strong antiproliferative activity against several stubborn cancer cells, including AsPC-1 cells (IC50 = 0.105 mu M), BxPC-3 cells (IC50 = 0.090 mu M), and MCF-7/ADR cells (IC50 = 0.59 mu M). Additionally, compound 7a also showed great antitumor efficacy in vivo via aAsPC-1 cancer Xenograft mouse model. The preliminary mechanism study by Western blot analysis revealed that 7a repressed FAK phosphorylation in AsPC cancer cells. Taken together, the results indicate that compound 7a may serve as a promising preclinical candidate for treatment of stubborn cancers. (C) 2019 Elsevier Masson SAS. All rights reserved.
• Bischoff, Chemische Berichte, 1900, vol. 33, p. 1605
  作者：Bischoff

  DOI：——

  日期：——